-
Signature
-
/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues
-
Issuer symbol
-
PBYI
-
Transactions as of
-
08 Jul 2025
-
Net transactions value
-
-$33,649
-
Form type
-
4
-
Filing time
-
10 Jul 2025, 20:56:09 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| NOUGUES MAXIMO F |
Chief Financial Officer |
C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES |
/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues |
10 Jul 2025 |
0001758507 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PBYI |
Common Stock |
Sale |
$19,739 |
-5,587 |
-2.6% |
$3.53 |
208,164 |
08 Jul 2025 |
Direct |
F1 |
| transaction |
PBYI |
Common Stock |
Sale |
$13,910 |
-3,935 |
-1.9% |
$3.54 |
204,229 |
09 Jul 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: